Form 4: Spero Therapeutics COO Sells Shares for Tax Obligations

Spero Therapeutics' Chief Operating Officer, Timothy Keutzer, sold 1,695 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Timothy Keutzer, Chief Operating Officer of Spero Therapeutics, Inc. (SPRO), reported a sale of common stock.
• The transaction involved 1,695 shares of SPRO common stock.
• The shares were sold at a price of $1.97 per share.
• The sale was executed on August 28, 2025.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) that were granted on August 26, 2021.
• Following this transaction, Mr. Keutzer beneficially owns 739,744 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations related to RSU vesting, which is a neutral event. It does not indicate a change in management's confidence or company performance.

Positives

• The transaction is a routine "sell to cover" for tax obligations, indicating the vesting of previously granted restricted stock units (RSUs), which is a positive for the executive's compensation.

Negatives

• A minor reduction in direct insider ownership, although for a routine tax purpose.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market risks associated with stock ownership.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, as it reports a past transaction.

Industry Context

This routine insider transaction, a 'sell to cover' for tax obligations, is a common occurrence across all industries when executive compensation includes restricted stock units. It does not reflect any specific industry trends or competitive positioning.

Comparison to Industry Standards

• A 'sell to cover' transaction for tax purposes is a standard practice for executives receiving equity compensation across publicly traded companies.
• It is not indicative of company-specific performance relative to peers but rather a mechanism to manage tax liabilities upon RSU vesting.
• No specific comparable companies or projects are relevant for this type of routine transaction.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a routine tax purpose, unlikely to significantly impact perception.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices.

Key Dates

Recommendation

This Form 4 filing reports a routine 'sell to cover' transaction by an executive to satisfy tax obligations upon RSU vesting. Such transactions are common and generally do not reflect a change in the company's fundamentals or the executive's long-term outlook. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based solely on this filing.

Keywords

Spero Therapeutics, SPRO, Form 4, Insider Trading, Stock Sale, Timothy Keutzer, Chief Operating Officer, Restricted Stock Units, RSU Vesting, Tax Withholding